• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Innospec Inc.

    2/19/25 6:09:17 AM ET
    $IOSP
    Major Chemicals
    Industrials
    Get the next $IOSP alert in real time by email
    8-K
    false 0001054905 0001054905 2025-02-18 2025-02-18

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Form 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): February 18, 2025

     

     

    INNOSPEC INC.

    (Exact name of registrant as specified in its charter)

     

     

    Commission File Number: 1-13879

     

    Delaware   98-0181725
    (State or other jurisdiction
    of incorporation)
     

    (IRS Employer

    Identification No.)

    8310 South Valley Highway, Suite 350

    Englewood, Colorado, 80112

    (Address of principal executive offices, including zip code)

    (303)792-5554

    (Registrant’s telephone number, including area code)

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of exchange

    on which registered

    Common Stock   IOSP   NASDAQ

     

     

     


    Item 2.02

    Results of Operations and Financial Condition.

    On February 18, 2025, Innospec Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2024 (the “Press Release”).

     

    Item 9.01.

    Financial Statements and Exhibits.

    (d) Exhibits.

    EXHIBIT INDEX

     

    Number

      

    Description

      

    Method of Filing

    99.1    Press Release dated February 18, 2025 announcing Innospec Inc.’s financial results for the fiscal year ended December 31, 2024.    Filed Herewith
    104    Cover Page Interactive Data File – the cover page XBRL tags are embedded within the Inline XBRL document.   


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

          INNOSPEC INC.
    Date: February 19, 2025     By:  

    /s/ David B. Jones

          David B. Jones
          Senior Vice President, General Counsel and Chief Compliance Officer
    Get the next $IOSP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IOSP

    DatePrice TargetRatingAnalyst
    4/21/2025$115.00Neutral → Buy
    Seaport Research Partners
    3/30/2022Neutral
    Seaport Research Partners
    More analyst ratings

    $IOSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Innospec upgraded by Seaport Research Partners with a new price target

      Seaport Research Partners upgraded Innospec from Neutral to Buy and set a new price target of $115.00

      4/21/25 8:30:53 AM ET
      $IOSP
      Major Chemicals
      Industrials
    • Seaport Research Partners initiated coverage on Innospec

      Seaport Research Partners initiated coverage of Innospec with a rating of Neutral

      3/30/22 7:37:48 AM ET
      $IOSP
      Major Chemicals
      Industrials

    $IOSP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Parrette Leslie J sold $40,421 worth of shares (446 units at $90.63), decreasing direct ownership by 8% to 5,497 units (SEC Form 4)

      4 - INNOSPEC INC. (0001054905) (Issuer)

      5/15/25 9:11:51 PM ET
      $IOSP
      Major Chemicals
      Industrials
    • SVP, HUMAN RESOURCES Griffin Hardy Louis Iii covered exercise/tax liability with 600 shares, decreasing direct ownership by 8% to 6,742 units (SEC Form 4)

      4 - INNOSPEC INC. (0001054905) (Issuer)

      5/15/25 9:05:37 PM ET
      $IOSP
      Major Chemicals
      Industrials
    • SVP, Corporate Dev and IR Barnes Corbin covered exercise/tax liability with 740 shares, decreasing direct ownership by 8% to 8,998 units (SEC Form 4)

      4 - INNOSPEC INC. (0001054905) (Issuer)

      5/15/25 9:01:11 PM ET
      $IOSP
      Major Chemicals
      Industrials